Dimethyl fumarate
- Generic Name
- Dimethyl fumarate
- Brand Names
- Tecfidera, Skilarence, Dimethyl fumarate Neuraxpharm, Dimethyl fumarate Mylan, Dimethyl fumarate Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C6H8O4
- CAS Number
- 624-49-7
- Unique Ingredient Identifier
- FO2303MNI2
- Background
Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis. The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress. Dimethyl fumarate is marketed under the brand name Tecfidera, and it was the third oral disease-modifying agent for multiple sclerosis approved by the FDA, following fingolimod and teriflunomide. Prior to its FDA approval, dimethyl fumarate had been used in Germany for treatment of psoriasis.
- Indication
Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
- Associated Conditions
- Clinically Isolated Syndrome (CIS), Relapsing Forms of MS, Relapsing Remitting Multiple Sclerosis (RRMS), Active Secondary Progressive Multiple Sclerosis (SPMS)
Tecfidera Diffusion Tensor Imaging
- Conditions
- Multiple Sclerosis, Dimethyl Fumarate, Diffusion Tensor Imaging Magnetic Resonance Imaging
- Interventions
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 115
- Registration Number
- NCT02686684
Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS
- Conditions
- Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis
- Interventions
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT02675413
- Locations
- 🇺🇸
Swedish Neuroscience Institute, Seattle, Washington, United States
🇺🇸Washington University (John L. Trotter MS Center), St. Louis, Missouri, United States
Tecfidera and MRI for Brain Energy in MS
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 4
- Registration Number
- NCT02644083
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Biogen
- Target Recruit Count
- 221
- Registration Number
- NCT02579681
- Locations
- 🇮🇹
Research site, Roma, Italy
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT02555215
- Locations
- 🇹🇷
Research Site, Ankara, Turkey
Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Universitätsmedizin Mannheim
- Target Recruit Count
- 25
- Registration Number
- NCT02546440
- Locations
- 🇩🇪
University Medical Center, Mannheim, Germany
Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
- Conditions
- Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis
- Interventions
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- Biogen
- Target Recruit Count
- 218
- Registration Number
- NCT02525874
- Locations
- 🇹🇷
Research Site, Umuttepe, Kocaeli, Turkey
Tecfidera Lymphocyte Chart Review
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 483
- Registration Number
- NCT02519413
- Locations
- 🇺🇸
Research site, Homewood, Alabama, United States
🇺🇸Research Site, Milwaukee, Wisconsin, United States
Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Other: Placebo
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2015-12-28
- Lead Sponsor
- Biogen
- Registration Number
- NCT02472938
Tecfidera and the Gut Microbiota
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: injectable MS DMT
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 36
- Registration Number
- NCT02471560
- Locations
- 🇳🇴
Research site, Stavanger, Norway
🇳🇴Research Site, Lillehammer, Norway
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.